2335 Analysis of activity, efficacy and safety of first line Nab Paclitaxel (Nab-P) and Gemcitabine (G) in advanced pancreatic cancer (APDAC) frail and elderly patients (pts)

Authors :: Jole Ventriglia
R. Conca
Vanja Vaccaro
L. Leo
V. Zagonel
A. Zaniboni
Francesca Bergamo
Enrico Vasile
Davide Melisi
F Andreozzi
Antonio Febbraro
G. Giordano
Eleonora Lucchini
Alessandro Passardi
F. De Vita
Gianna Musettini
M. Milella
Roberta Marciano
Marco Russano
Paola Bertocchi
Source :: European Journal of Cancer. 51:S445
Publication Year :: 2015
Publisher :: Elsevier BV, 2015.

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
business.industry
First line
medicine.disease
Gemcitabine
Pancreatic cancer
Internal medicine
medicine
business
Nab-paclitaxel
medicine.drug

Full Text Access

Tools